James Moser, MD


A. James Moser, M.D., F.A.C.S., is Co-Director of the Pancreas and Liver Institute at Beth Israel Deaconess Medical Center and Associate Professor of Surgery at Harvard Medical School.

Dr. Moser graduated from Princeton University and received his medical degree from Washington University School of Medicine in St. Louis, MO. He completed General Surgery residency and research fellowship in membrane biology at UCLA Center for Health Sciences and UCLA School of Medicine in Los Angeles, CA. Dr. Moser was Co-Director of the Pancreatic Cancer Center at University of Pittsburgh Medical Center and pioneered the application of robotic technology to complex pancreatic diseases to reduce the pain of surgery and stress of treatment. He has advanced surgical training and is a leader in complex, advanced surgical oncology including vascular resection, minimally-invasive surgery, and pancreatic auto-islet transplantation.

Dr. Moser was recruited to Beth Israel Deaconess Medical Center in 2012 as the inaugural Executive Director of the Institute for Hepatobiliary and Pancreatic Surgery. He provides leadership, strategic vision, and integration of surgery programs for pancreatic, hepatic, and biliary diseases to establish world-class multidisciplinary programs based on innovative clinical surgery and translational research. Dr. Moser is Co-Director of the multidisciplinary BIDMC Pancreas and Liver Institute together with Dr. Simon Robson, Chief of BIDMC Gastroenterology and Hepatology. The Pancreas and Liver Institute combines key BIDMC strengths in Advanced Endoscopy with advanced minimally-invasive and robotic surgery, integrated patient-centered multidisciplinary care for pancreas and liver diseases, and leadership of innovative clinical trials within the Dana Farber Harvard Cancer Center. He directs BIDMC’s multidisciplinary Pancreatic Cancer Center and is co-director of the weekly Harvard CME-approved HepatoPancreaticoBiliary multidisciplinary conference.

Dr. Moser’s has been Principal Investigator of a grant funded by the National Institutes of Health and has received funding for three investigator-initiated clinical trials for pancreatic cancer. He is currently Co-Principal Investigator for Project Survival™, a joint venture between BIDMC, the Cancer Research and Biostatistics/Pancreatic Cancer Research Team, and Berg Pharma to develop early prognostic and therapeutic biomarkers for pancreatic cancer, a large research collaborative effort with a total cost of $23 million. His current research group includes 8 research fellows, including a Fulbright scholar and three master’s students in the Harvard School of Public Health. The team is supported by a large community of grateful patients and families funding patient-centered care for pancreatic cancer through the Alliance of Families Fighting Pancreatic Cancer. He has published over 100 times and is an active participant in multiple national and international societies including the Society of Surgical Oncology, American Hepato-Pancreato-Biliary Association, and the Society of American Gastrointestinal and Endoscopic Surgeons.